No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE).
Surya Panicker RajeevCarl Alexander RobertsEmily BrownVictoria S SprungJo A HarroldJason C G HalfordAndrej StancakEmma J BoylandGraham J KempJulie PerryElaine HowarthRichard JacksonAndrew WiemkenRichard SchwabDaniel J CuthbertsonJohn P H WildingPublished in: Diabetes, obesity & metabolism (2023)
The reduction in body weight and liver fat with dapagliflozin was not associated with compensatory adaptations in food intake or energy expenditure.